Difference between revisions of "Team:Freiburg/Overview"
| Line 1: | Line 1: | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
<html> | <html> | ||
| − | <div class="column full_size" > | + | <div class="column full_size" > |
<div class="color13"> | <div class="color13"> | ||
<div class="para_center_20"> | <div class="para_center_20"> | ||
| Line 591: | Line 586: | ||
transform="matrix(1 0 0 1 100 75)"> | transform="matrix(1 0 0 1 100 75)"> | ||
<text | <text | ||
| − | x=" | + | x="500" |
y="600" | y="600" | ||
| − | text-anchor=" | + | text-anchor="left" |
font-size="24" | font-size="24" | ||
font-family="Arial" | font-family="Arial" | ||
| Line 772: | Line 767: | ||
transform="matrix(1 0 0 1 100 75)"> | transform="matrix(1 0 0 1 100 75)"> | ||
<text | <text | ||
| − | x=" | + | x="500" |
y="600" | y="600" | ||
| − | text-anchor=" | + | text-anchor="left" |
font-size="24" | font-size="24" | ||
font-family="Arial" | font-family="Arial" | ||
fill="brown" | fill="brown" | ||
| − | id="text4228">Carcinoembryonic antigen (CEA) is an adherence molecule on cell surface of the cells.</text> | + | id="text4228"> |
| + | <tspan x="500" y="600">Carcinoembryonic antigen (CEA) is an adherence molecule</tspan> | ||
| + | <tspan x="500" y="630">on cell surface of the cells.</tspan> | ||
| + | </text> | ||
</g> | </g> | ||
<g | <g | ||
| Line 1,323: | Line 1,321: | ||
transform="matrix(1 0 0 1 100 75)"> | transform="matrix(1 0 0 1 100 75)"> | ||
<text | <text | ||
| − | + | text-anchor="left" | |
| − | + | ||
| − | text-anchor=" | + | |
font-size="24" | font-size="24" | ||
font-family="Arial" | font-family="Arial" | ||
fill="blue" | fill="blue" | ||
| − | id="text5416"> | + | id="text5416"> |
| + | <tspan x="500" y="600">To gain multivalency a carrier is used.</tspan> | ||
| + | <tspan x="500" y="630">The endospores of bacillus subtilis provide an excelent vehicle.</tspan></text> | ||
</g> | </g> | ||
<g | <g | ||
| Line 1,494: | Line 1,492: | ||
transform="matrix(1 0 0 1 100 75)"> | transform="matrix(1 0 0 1 100 75)"> | ||
<text | <text | ||
| − | + | text-anchor="left" | |
| − | + | ||
| − | text-anchor=" | + | |
font-size="24" | font-size="24" | ||
font-family="Arial" | font-family="Arial" | ||
fill="yellow" | fill="yellow" | ||
| − | id="text5173"><Glutathion-S-Transferase (GST) is an enzyme that converts our prodrug Azathioprine into 6-Mercaptopurine. </text> | + | id="text5173"> |
| + | <tspan x="500" y="600">Glutathion-S-Transferase (GST) is an enzyme that converts</tspan> | ||
| + | <tspan x="500" y="630">our prodrug Azathioprine into 6-Mercaptopurine.</tspan> | ||
| + | </text> | ||
</g> | </g> | ||
<g | <g | ||
| Line 1,579: | Line 1,578: | ||
transform="matrix(1 0 0 1 100 75)"> | transform="matrix(1 0 0 1 100 75)"> | ||
<text | <text | ||
| − | + | text-anchor="left" | |
| − | + | ||
| − | text-anchor=" | + | |
font-size="24" | font-size="24" | ||
font-family="Arial" | font-family="Arial" | ||
fill="green" | fill="green" | ||
| − | id="text4939">Nanobodies are used to bind to carcinoembryonic antigen (CEA). Nanobodies are highly specific single-domain antibodies. </text> | + | id="text4939"> |
| + | <tspan x="500" y="600">Nanobodies are used to bind to carcinoembryonic antigen (CEA).</tspan> | ||
| + | <tspan x="500" y="630">Nanobodies are highly specific single-domain antibodies.</tspan> | ||
| + | </text> | ||
</g> | </g> | ||
<g | <g | ||
| Line 1,674: | Line 1,674: | ||
transform="matrix(1 0 0 1 100 75)"> | transform="matrix(1 0 0 1 100 75)"> | ||
<text | <text | ||
| − | + | text-anchor="left" | |
| − | + | ||
| − | text-anchor=" | + | |
font-size="24" | font-size="24" | ||
font-family="Arial" | font-family="Arial" | ||
fill="purple" | fill="purple" | ||
| − | id="text4710">Azathioprine is an inactive prodrug that gets into the colon with enteric-coated capsules.</text> | + | id="text4710"> |
| + | <tspan x="500" y="600">Azathioprine is an inactive prodrug that gets into the colon</tspan> | ||
| + | <tspan x="500" y="630">with enteric-coated capsules.</tspan> | ||
| + | </text> | ||
</g> | </g> | ||
<g | <g | ||
Revision as of 00:53, 18 October 2016
Overview
The treatment of diseases while avoiding systemic side effects is still a major obstacle in modern medicine. After administration, conventional drugs are distributed throughout the whole body thus affecting both, diseased and healthy cells. Current strategies on targeted drug delivery are mainly based on the applications of antibody-drug conjugates or nanoparticles. However, both approaches revealed considerable challenges in their application due to short half-life and expensive production, respectively. We develop a novel platform for targeted drug delivery by implementing highly specific nanobodies directed against surface markers of affected cells. The combination with an enzymatic functionality facilitates the local activation of prodrugs, thus preventing unnecessary side effects by systemic drug dispersal. By engineering the spores of probiotic Bacillus subtilis, a member of the human microbiome, we establish a low-cost carrier for well-tolerated treatment.
